Everyday Health on MSN
There’s a New Drug for Motion Sickness — the First in 40 Years
The FDA approved the pill Nereus (tradipitant) as a new treatment for vomiting caused by motion sickness, with fewer side ...
Tradipitant is a selective human substance P/neurokinin-1 receptor antagonist approved for the prevention of vomiting induced by motion in adults.
Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) approving a novel oral pill that helps prevent motion-induced vomiting – the first ...
Analysts raise price targets for Vanda Pharmaceuticals after FDA approved a motion sickness drug, citing growth potential.
Stocktwits on MSN
VNDA stock on track to open at three-year high – FDA clears first new motion sickness drug in decades
Two Phase 3 real-world trials, conducted on boats, showed that NEREUS significantly reduced vomiting compared with placebo. ・Vanda is also advancing Tradipitant in clinical development for ...
Does motion sickness turn you into a green, spewing mess? For plenty of people, the answer is yes. Current remedies may or ...
MedPage Today on MSN
FDA Greenlights First Motion Sickness Drug in More Than 40 Years
The scopolamine skin patch (Transderm Scōp), approved in 1979, was the last drug sanctioned by the FDA to prevent motion sickness. Most motion sickness cases are mild, but an estimated 5% to 15% of ...
WASHINGTON, Dec. 30, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral ...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA approval of NEREUS for the prevention of vomiting induced by motion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback